Princeton-based pharmaceutical company Soligenix announced today the closing of its $7.1 million public offering. The closing included 6. 7 million shares of common stock as well as five-year warrants to purchase up to 5.08 million shares of common.
Soligenix focuses on developing products to treat inflammatory diseases and biodefense countermeasures. According to the announcement, investors included an affiliated fund of Third Security LLC, a venture capital firm founded by R.J. Kirk and members of the company's management and board.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy